Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (830 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
A neurotoxic isoxazole isolated from species of amanita. It is obtained by decarboxylation of ibotenic acid. Muscimol is a potent agonist of gaba-a receptors and is used mainly as an experimental tool in animal and tissue studies.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Agarin; Pantherine.
Where it fits in the MeSH classification
- Broader topics
- Oxazoles; Mycotoxins
- See also
- Receptors, GABA-A
Related concepts
- Amanita
- Ibotenic Acid
- Gaba-A Receptors
Research landscape
PubMed indexes 4,774 records tagged with the MeSH heading “Muscimol” (counts retrieved 2026-10-31). 209 of them (4.4%) were published from 2020 onward, and the busiest period so far is through 1999 with 2,524 records.
Reviews account for 97 records (2.0%) and meta-analyses for 0. Randomized controlled trials number 2 (0.0%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.
Show the data
| Period | Records |
|---|---|
| through 1999 | 2,524 |
| 2000-2009 | 1,150 |
| 2010-2019 | 891 |
| 2020 onward | 209 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 97 | 2.0% |
| Meta-analyses | 0 | 0.0% |
| Randomized controlled trials | 2 | 0.0% |
Method: PubMed query "Muscimol"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.
Reading the evidence in drugs and chemicals
Studies of a chemical or drug can answer very different questions: what it is and how it behaves in cells and animals, how the body handles it, and whether it changes outcomes in people. Laboratory and animal findings often do not carry over to patients, and observational studies of exposures are confounded by who uses a substance and why. Nothing on this page is a recommendation to use, avoid, start or stop any substance or medicine; talk to a qualified clinician or pharmacist about your own situation. Check the dose, the species, the comparison group and whether a patient-relevant outcome was measured.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
| Study / authors | Year | Source label / design | Europe PMC citations | Licence / source |
|---|---|---|---|---|
| GABA and muscimol as reversible inactivation tools in learning and memory | 2000 | Review article Design not recorded in structured metadata | 45 | cc by PMID 10709211 · DOI · PMC2565374 |
| Updating of action-outcome associations is prevented by inactivation of the posterior pedunculopontine tegmental nucleus | 2013 | Research article Design not recorded in structured metadata | 30 | cc by PMID 23567109 · DOI · PMC3660625 |
| Extrasynaptic δ-GABAA receptors are high-affinity muscimol receptors | 2019 | Research article Design not recorded in structured metadata | 24 | cc by PMID 30565258 · DOI · PMC6438731 |
| Ibotenic Acid and Muscimol in Amanita muscaria: Chemistry, Sources of Variability, Analytical Determination, and Toxicological Significance | 2026 | Review article Design not recorded in structured metadata | 0 | cc by PMID 42796518 · DOI · PMC13609693 |
GABA and muscimol as reversible inactivation tools in learning and memory [1]
Abstract reading summary — source excerpts
- Opening excerpt
- Reversible inactivation of brain areas is a useful method for inferring brain-behavior relationships.
- Closing excerpt
- A critical analysis of data, collected in collaboration with Simon Brailowsky, with chronic GABA infusion is presented, together with an illustration of data obtained with muscimol-induced inactivation.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (89 words)
Reversible inactivation of brain areas is a useful method for inferring brain-behavior relationships. Infusion of GABA or of the GABA receptor agonist muscimol is considered one interesting reversible inactivation method because it may not affect fibers of passage and may therefore be compared to axon-sparing types of lesions. This article reviews the data obtained with this method in learning and memory experiments. A critical analysis of data, collected in collaboration with Simon Brailowsky, with chronic GABA infusion is presented, together with an illustration of data obtained with muscimol-induced inactivation.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 10709211 · DOI · PMC2565374
Updating of action-outcome associations is prevented by inactivation of the posterior pedunculopontine tegmental nucleus [2]
Abstract reading summary — source excerpts
- Opening excerpt
- The pedunculopontine tegmental nucleus (PPTg) is in a pivotal position between the basal ganglia and brainstem: it is able to influence and regulate all levels of basal ganglia and corticostriatal activity as well as being a key component of brainstem reticular and motor control circuitry.
- Closing excerpt
- These results are consistent with a role for the PPTg in 'higher-order' associative learning and are the first to demonstrate a brainstem role in action-outcome learning.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (245 words)
The pedunculopontine tegmental nucleus (PPTg) is in a pivotal position between the basal ganglia and brainstem: it is able to influence and regulate all levels of basal ganglia and corticostriatal activity as well as being a key component of brainstem reticular and motor control circuitry. Consistent with its anatomical position, the PPTg has previously been shown to process rapid, salient sensory input, is a target for Parkinson's disease treatments and has been implicated in associative learning. We explicitly investigated the role of the posterior pPPTg (pPPTg) in action-outcome processes, where actions are performed with the goal-directed aim of obtaining an anticipated outcome. We assessed rats' sensitivity to degradation of the contingency between actions (lever pressing) and outcomes (food reward) during either inactivation of pPPTg by microinjection of the GABA agonist muscimol or control infusions of saline. In response to the degradation of contingency between lever press and food reward, saline treated rats rapidly reduced rates of lever pressing whereas muscimol treated rats (pPPTg inactivation) maintained previous lever pressing rates. In contrast, when the contingency between lever press and food reward was unchanged saline and muscimol treated rats maintained their previous rates of lever pressing. This shows that the pPPTg is critically required for updating associations between actions and outcomes, but not in the continued performance of previously learned associations. These results are consistent with a role for the PPTg in 'higher-order' associative learning and are the first to demonstrate a brainstem role in action-outcome learning.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 23567109 · DOI · PMC3660625
Extrasynaptic δ-GABAA receptors are high-affinity muscimol receptors [3]
Abstract reading summary — source excerpts
- Opening excerpt
- Muscimol, the major psychoactive ingredient in the mushroom Amanita muscaria, has been regarded as a universal non-selective GABA-site agonist.
- Closing excerpt
- We conclude that biochemical and behavioral low-dose muscimol selectivity for δ-subunit-containing receptors is a result of low nanomolar-binding affinity on δ-GABAA Rs.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (255 words)
Muscimol, the major psychoactive ingredient in the mushroom Amanita muscaria, has been regarded as a universal non-selective GABA-site agonist. Deletion of the GABAA receptor (GABAA R) δ subunit in mice (δKO) leads to a drastic reduction in high-affinity muscimol binding in brain sections and to a lower behavioral sensitivity to muscimol than their wild type counterparts. Here, we use forebrain and cerebellar brain homogenates from WT and δKO mice to show that deletion of the δ subunit leads to a > 50% loss of high-affinity 5 nM [3 H]muscimol-binding sites despite the relatively low abundance of δ-containing GABAA Rs (δ-GABAA R) in the brain. By subtracting residual high-affinity binding in δKO mice and measuring the slow association and dissociation rates we show that native δ-GABAA Rs in WT mice exhibit high-affinity [3 H]muscimol-binding sites (KD ~1.6 nM on α4βδ receptors in the forebrain and ~1 nM on α6βδ receptors in the cerebellum at 22°C). Co-expression of the δ subunit with α6 and β2 or β3 in recombinant (HEK 293) expression leads to the appearance of a slowly dissociating [3 H]muscimol component. In addition, we compared muscimol currents in recombinant α4β3δ and α4β3 receptors and show that δ subunit co-expression leads to highly muscimol-sensitive currents with an estimated EC50 of around 1-2 nM and slow deactivation kinetics. These data indicate that δ subunit incorporation leads to a dramatic increase in GABAA R muscimol sensitivity. We conclude that biochemical and behavioral low-dose muscimol selectivity for δ-subunit-containing receptors is a result of low nanomolar-binding affinity on δ-GABAA Rs.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 30565258 · DOI · PMC6438731
Ibotenic Acid and Muscimol in Amanita muscaria: Chemistry, Sources of Variability, Analytical Determination, and Toxicological Significance [4]
Abstract reading summary — source excerpts
- Opening excerpt
- Amanita muscaria contains two structurally related neuroactive isoxazole metabolites, ibotenic acid (IA) and muscimol (MUS), which differ markedly in pharmacological activity.
- Closing excerpt
- Toxicological interpretation additionally requires consideration of total dose, preparation, matrix composition, and individual susceptibility.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (241 words)
Amanita muscaria contains two structurally related neuroactive isoxazole metabolites, ibotenic acid (IA) and muscimol (MUS), which differ markedly in pharmacological activity. IA acts as an agonist at NMDA and metabotropic glutamate receptors, whereas MUS is a potent GABAergic agonist. This review critically evaluates their chemistry and biosynthesis, biological variability, post-harvest transformation, analytical determination, and toxicological significance. Direct evidence demonstrates interspecific variation within Amanita section Amanita. Developmental evidence for A. muscaria is limited but direct: an older maturation study identified tissue-dependent changes in IA and MUS, while concentrations calculated for the whole fruiting body remained comparatively stable; observations in A. subglobosa provide additional species-specific evidence. Controlled studies also demonstrate processing-related changes during drying and heating, whereas storage effects remain condition-dependent and less completely characterized. Cross-study comparison is constrained by differences in species identification, tissue selection, developmental stage, hydration, sample handling, normalization, and analytical procedure. Quantitative study-level comparison shows that LC-MS/MS and UHPLC-MS/MS, capillary electrophoresis, GC-MS, NMR, and rapid ambient-MS approaches serve different matrices and analytical purposes. Their reported sensitivity, recovery, precision, and calibration performance cannot be ranked directly across studies, and matrix-specific validation remains essential. Broader fungal research provides mechanistic context for possible environmental regulation, but direct controlled evidence for stress-dependent IA biosynthesis in A. muscaria remains sparse. The IA/MUS ratio is best treated as a secondary chemical descriptor alongside absolute concentrations and a clearly defined normalization basis. Toxicological interpretation additionally requires consideration of total dose, preparation, matrix composition, and individual susceptibility.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42796518 · DOI · PMC13609693
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article Binsing studies with muscimol; relation ty synaptic gamma-aminobutyrate receptors [5]
- Research article Muscimol as an ionotropic GABA receptor agonist [6]
- Research article Fungal hallucinogens psilocin, ibotenic acid, and muscimol: analytical methods and biologic activities [7]
- Research article Physiological and behavioral studies with muscimol [8]
- Research article Muscimol, a psychoactive constituent of Amanita muscaria, as a medicinal chemical model structure [9]
- Research article Classics in Chemical Neuroscience: Muscimol [10]
References
- Majchrzak M, Di Scala G. GABA and muscimol as reversible inactivation tools in learning and memory. . 2000. PMID 10709211 · DOI · PMC2565374
- Maclaren DA, Wilson DI, Winn P. Updating of action-outcome associations is prevented by inactivation of the posterior pedunculopontine tegmental nucleus. . 2013. PMID 23567109 · DOI · PMC3660625
- Benkherouf AY, Taina KR, Meera P, Aalto AJ, Li XG, Soini SL, et al.. Extrasynaptic δ-GABAA receptors are high-affinity muscimol receptors. . 2019. PMID 30565258 · DOI · PMC6438731
- Günther A, Bednarczyk-Cwynar B, Tomczyk M. Ibotenic Acid and Muscimol in Amanita muscaria: Chemistry, Sources of Variability, Analytical Determination, and Toxicological Significance. . 2026. PMID 42796518 · DOI · PMC13609693
- DeFeudis FV. Binsing studies with muscimol; relation ty synaptic gamma-aminobutyrate receptors. Neuroscience. 1980. PMID 6248815 · DOI
- Johnston GA. Muscimol as an ionotropic GABA receptor agonist. Neurochem Res. 2014. PMID 24473816 · DOI
- Stebelska K. Fungal hallucinogens psilocin, ibotenic acid, and muscimol: analytical methods and biologic activities. Ther Drug Monit. 2013. PMID 23851905 · DOI
- DeFeudis FV. Physiological and behavioral studies with muscimol. Neurochem Res. 1980. PMID 6258091 · DOI
- Krogsgaard-Larsen P, Brehm L, Schaumburg K. Muscimol, a psychoactive constituent of Amanita muscaria, as a medicinal chemical model structure. Acta Chem Scand B. 1981. PMID 6274117 · DOI
- Rivera-Illanes D, Recabarren-Gajardo G. Classics in Chemical Neuroscience: Muscimol. ACS Chem Neurosci. 2024. PMID 39254100 · DOI
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-31.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.